Goodwin Procter advised STALICLA on the deal. STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here